Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jul 31;31(12):1765-1769.
doi: 10.1097/QAD.0000000000001543.

A commitment contract to achieve virologic suppression in poorly adherent patients with HIV/AIDS

Marcella Alsan  1 , John Beshears, Wendy S Armstrong, James J Choi, Brigitte C Madrian, Minh Ly T Nguyen, Carlos Del Rio, David Laibson, Vincent C Marconi
Affiliations
Randomized Controlled Trial

A commitment contract to achieve virologic suppression in poorly adherent patients with HIV/AIDS

Marcella Alsan et al. AIDS. .

Abstract

Objective: Assess whether a commitment contract informed by behavioral economics leads to persistent virologic suppression among HIV-positive patients with poor antiretroviral therapy (ART) adherence.

Design: Single-center pilot randomized clinical trial and a nonrandomized control group.

Setting: Publicly funded HIV clinic in Atlanta, Georgia, USA.

Intervention: The study involved three arms. First, participants in the provider visit incentive (PVI) arm received $30 after attending each scheduled provider visit. Second, participants in the incentive choice arm were given a choice between the above arrangement and a commitment contract that made the $30 payment conditional on both attending the provider visit and meeting an ART adherence threshold. Third, the passive control arm received routine care and no incentives.

Participants: A total of 110 HIV-infected adults with a recent plasma HIV-1 viral load more than 200 copies/ml despite ART. The sample sizes of the three groups were as follows: PVI, n = 21; incentive choice, n = 19; and passive control, n = 70.

Main outcome measure: Virologic suppression (plasma HIV-1 viral load ≤200 copies/ml) at the end of the incentive period and at an unanticipated postincentive study visit approximately 3 months later.

Results: The odds of suppression were higher in the incentive choice arm than in the passive control arm at the postincentive visit (adjusted odds ratio 3.93, 95% confidence interval 1.19-13.04, P = 0.025). The differences relative to the passive control arm at the end of the incentive period and relative to the PVI arm at both points in time were not statistically significant.

Conclusion: Commitment contracts can improve ART adherence and virologic suppression.

Trial registration: ClinicalTrials.gov identifier NCT01455740.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the Corresponding Author) and declare: no support from any organization for the submitted work other than from the National Institutes of Health (P30AG034532), the Emory University Center for AIDS Research (P30AI050409), and the Pershing Square Fund for the Foundations of Human Behavior; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work, with the exception of the following: David Laibson is a member of the Scientific Advisory Board of the pharmacy benefit management company Express Scripts, a position for which he does not receive compensation.

Figures

Figure 1
Figure 1
Percent Virologically Suppressed by Study Arm and Visit Number
See this image and copyright information in PMC

References

    1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30. - PubMed
    1. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–1183. - PubMed
    1. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17(10):756–765. - PMC - PubMed
    1. Ickovics J, Meade C. Adherence to antiretroviral therapy among patients with HIV: A critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):98–102. - PubMed
    1. Kalichman SC, Grebler T. Stress and poverty predictors of treatment adherence among people with low-literacy living with HIV/AIDS. Psychosom Med. 2010;72(8):810–816. - PMC - PubMed

Publication types

Substances

Associated data